Published • loading... • Updated
For the First Time Since Its Listing in 2003, the Revenue of "Pien Tze Huang," Often Referred to as the "Moutai of Chinese Medicine," Has Declined. | Net Profit | Bubble | Time-Honored Chinese Brand
Summary by 大纪元 Epoch Times
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (Pien Tze Huang) reported operating revenue of RMB 9.001 billion in 2025, a year-on-year decrease of 16.56%; net profit attributable to shareholders decreased by 27.49% year-on-year. This marks the first time Pien Tze Huang has experienced an annual revenue decline since its listing in 2003. Furthermore, in the first quarter of 2026, Pien Tze Huang continued the trend of declining revenue and net…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
